Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study
| Autor: | Christiane Copie-Bergman, Jehan Dupuis, Iradj Sobhani, Karim Belhadj, Aurelien Amiot, Karen Leroy, Yann Le Baleur, Marie-Hélène Delfau-Larue, Corinne Haioun, Jean-Charles Delchier, Michael J. Levy, Francois Hemery |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Randomization Oncogene Proteins Fusion Gastroenterology Translocation Genetic Antibodies Monoclonal Murine-Derived Stomach Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Gastric mucosa Humans B cell Aged Neoplasm Staging Aged 80 and over Chlorambucil business.industry Chromosomes Human Pair 11 Lymphoma B-Cell Marginal Zone Hematology Middle Aged medicine.disease Lymphoma Surgery Treatment Outcome medicine.anatomical_structure Lymphatic system Oncology Monoclonal Female Rituximab Chromosomes Human Pair 18 business medicine.drug |
| Zdroj: | Leukemia & Lymphoma. 54:940-944 |
| ISSN: | 1029-2403 1042-8194 |
| Popis: | Forty-nine patients, t(11;18)-positive (n = 31) and t(11;18)-negative (n = 18), were treated without randomization with rituximab-chlorambucil or rituximab alone. Evaluation was performed at week (W) 6, week (W) 25 and every 6 months (Wx). Comparing the rituximab-chlorambucil group to the rituximab-alone group, remission was obtained in 93% vs. 66% at W6 (p = 0.01), in 93% vs. 81% at W25 (p = 0.14) and in 93% vs. 76% at Wx (p = 0.07). Comparing the rituximab-chlorambucil group to the rituximab-alone group in t(11;18)-positive patients, remission was obtained in 100% vs. 45% at W6 (p = 0.0005), in 100% vs. 66% at W25 (p = 0.01) and in 96% vs. 55% at Wx (p = 0.01). Comparing the rituximab-chlorambucil group to the rituximab-alone group in t(11;18)-negative patients, remission was obtained in 66% vs. 83% at W6 (p = 0.32), in 66% vs. 92% at W25 (p = 0.22) and in 83% vs. 92% at Wx (p = 0.47). In conclusion, rituximab-chlorambucil is significantly more rapidly efficient than rituximab alone. In t(11;18)-positive patients, the combination is more efficient than rituximab alone. In t(11;18)-negative patients, rituximab alone is as efficient as rituximab-chlorambucil and may be an alternative treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|